EuroBiotech Report—Novartis’ CAR-T data; Bioblast seeks help; Merck KGaA, F-Star partner; Novo and Innate in I-O pact

Welcome to the latest edition of our weekly EuroBiotech Report. We started the week with two big deals for European biopharmas as German Merck and the U.K.’s F-Star penned a new bispecific R&D deal, while Innate gained exclusive rights to Novo’s first-in-class clinical-stage anti-C5aR antibody, as Novo boosted its stake in the French biotech. And then, after ASCO, we saw Novartis reveal its long-awaited Juliet CAR-T data while Israel’s Bioblast has sought out life sciences advisory firm JSB-Partners to help it find either a partner or merger deal. Ben Adams. 

  1. As Novartis preps for first CAR-T FDA AdComm, Juliet data revealed

It’s been a big week for CAR-T: Novartis, Juno, Kite, Bluebird Bio and Nanjing Legend Biotech all posted positive data for the cutting-edge experimental cancer class at ASCO, and now Novartis has revealed the long-awaited interim Juliet data for its CAR-T candidate at a Swiss conference. As it goes head-to-head with rival Kite Pharma.

  1. Israel's troubled Bioblast seeks partners, merger

Several months after abandoning plans for a securities offering, Israel’s Bioblast Pharma has asked JSB-Partners to help it seek out a partner or a merger to help lift it out of its troubles.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.
  1. Merck KGaA, F-Star in bispecific biobucks bonanza deal

The two countries’ governments may not be getting along right now as a long divorce plays out, but it’s a marriage of science for Germany’s Merck and Cambridge, U.K.-based F-Star as the two pair up for a new bispecific research deal.

  1. Innate Pharma and Novo Nordisk pen early I-O cancer drug deal

French biotech Innate Pharma has inked a new deal with Danish diabetes specialist Novo Nordisk that sees the latter boost its stake in the firm while Innate get its hands on a new I-O candidate.

And more articles of note >>

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.